Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.340
-0.060 (-4.29%)
At close: Apr 24, 2026, 4:00 PM EDT
1.330
-0.010 (-0.75%)
After-hours: Apr 24, 2026, 7:30 PM EDT
Allarity Therapeutics Employees
As of December 31, 2025, Allarity Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$40,000
Profits / Employee
-$1,403,875
Market Cap
21.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2024 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2023 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2022 | 9 | -4 | -30.77% | 9 | 0 |
| Dec 31, 2021 | 13 | -1 | -7.14% | 13 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 38 |
| OSR Holdings | 22 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| NewcelX | 15 |
| VYNE Therapeutics | 10 |
| Cocrystal Pharma | 10 |
ALLR News
- 26 days ago - Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - GlobeNewsWire
- 7 weeks ago - Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - GlobeNewsWire
- 2 months ago - Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders - GlobeNewsWire
- 5 months ago - Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - GlobeNewsWire
- 7 months ago - Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 - GlobeNewsWire